Literature DB >> 22661378

Botulinum toxin for the treatment of movement disorders.

Mary Ann Thenganatt1, Stanley Fahn.   

Abstract

After botulinum toxin was initially used to treat strabismus in the 1970s, others started using it to treat movement disorders including blepharospasm, hemifacial spasm, cervical dystonia, spasmodic dysphonia, and oromandibular dystonia. It was discovered that botulinum toxin can be an effective treatment for focal movement disorders with limited side effects. Over the past three decades, various formulations of botulinum toxin have been developed and the therapeutic use of these toxins has expanded in movement disorders and beyond. We review the history and mechanism of action of botulinum toxin, as well as describe different formulations available and their potential therapeutic uses in movement disorders.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22661378     DOI: 10.1007/s11910-012-0286-3

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  103 in total

1.  Botulinum toxin antibody testing: comparison between the immunoprecipitation assay and the mouse diaphragm assay.

Authors:  D Dressler; G Dirnberger
Journal:  Eur Neurol       Date:  2001       Impact factor: 1.710

2.  Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial.

Authors:  R Tintner; R Gross; U F Winzer; K A Smalky; J Jankovic
Journal:  Neurology       Date:  2005-09-13       Impact factor: 9.910

3.  Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up.

Authors:  J J M Kruisdijk; J H T M Koelman; B W Ongerboer de Visser; R J de Haan; J D Speelman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-21       Impact factor: 10.154

4.  Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences.

Authors:  H Göschel; K Wohlfarth; J Frevert; R Dengler; H Bigalke
Journal:  Exp Neurol       Date:  1997-09       Impact factor: 5.330

5.  Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.

Authors:  Daniel Truong; Drake D Duane; Joseph Jankovic; Carlos Singer; Lauren C Seeberger; Cynthia L Comella; Mark F Lew; Robert L Rodnitzky; Fabio O Danisi; James P Sutton; P David Charles; Robert A Hauser; Geoffrey L Sheean
Journal:  Mov Disord       Date:  2005-07       Impact factor: 10.338

6.  Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor.

Authors:  J Wissel; F Masuhr; L Schelosky; G Ebersbach; W Poewe
Journal:  Mov Disord       Date:  1997-09       Impact factor: 10.338

7.  Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia.

Authors:  D D Troung; M Rontal; M Rolnick; A E Aronson; K Mistura
Journal:  Laryngoscope       Date:  1991-06       Impact factor: 3.325

8.  Botulinum toxin therapy for abductor spasmodic dysphonia.

Authors:  Gayle Woodson; Heidi Hochstetler; Thomas Murry
Journal:  J Voice       Date:  2005-08-26       Impact factor: 2.009

9.  Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A.

Authors:  P E Greene; S Fahn
Journal:  Mov Disord       Date:  1993-10       Impact factor: 10.338

10.  Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity.

Authors:  Petr Kanovský; Jaroslaw Slawek; Zoltan Denes; Thomas Platz; Irena Sassin; Georg Comes; Susanne Grafe
Journal:  Clin Neuropharmacol       Date:  2009 Sep-Oct       Impact factor: 1.592

View more
  13 in total

Review 1.  Treatment of dystonia.

Authors:  Mary Ann Thenganatt; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

2.  Flu-like symptoms and associated immunological response following therapy with botulinum toxins.

Authors:  José Fidel Baizabal-Carvallo; Joseph Jankovic; Jordan Feld
Journal:  Neurotox Res       Date:  2013-05-16       Impact factor: 3.911

3.  Responsiveness to botulinum toxin type A in muscles of complex regional pain patients with tonic dystonia.

Authors:  Johanna C M Schilder; J Gert van Dijk; Dirk Dressler; Johannes H T M Koelman; Johan Marinus; Jacobus J van Hilten
Journal:  J Neural Transm (Vienna)       Date:  2014-02-15       Impact factor: 3.575

4.  Safe Administration of Botulinum Toxin Type A Injections During Pregnancy: A Report of Two Cases.

Authors:  Henriette Krug; Patricia Krause; Andreas Kupsch; Andrea A Kühn
Journal:  Mov Disord Clin Pract       Date:  2015-05-06

Review 5.  Botulinum Toxin for Neuropathic Pain: A Review of the Literature.

Authors:  Hyun-Mi Oh; Myung Eun Chung
Journal:  Toxins (Basel)       Date:  2015-08-14       Impact factor: 4.546

6.  OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study.

Authors:  Danièle Ranoux; Gaelle Martiné; Gaëlle Espagne-Dubreuilh; Marlène Amilhaud-Bordier; François Caire; Laurent Magy
Journal:  J Headache Pain       Date:  2017-07-21       Impact factor: 7.277

Review 7.  Botulinum Toxin for the Treatment of Neuropathic Pain.

Authors:  JungHyun Park; Hue Jung Park
Journal:  Toxins (Basel)       Date:  2017-08-24       Impact factor: 4.546

Review 8.  Closed-loop brain-machine-body interfaces for noninvasive rehabilitation of movement disorders.

Authors:  Frédéric D Broccard; Tim Mullen; Yu Mike Chi; David Peterson; John R Iversen; Mike Arnold; Kenneth Kreutz-Delgado; Tzyy-Ping Jung; Scott Makeig; Howard Poizner; Terrence Sejnowski; Gert Cauwenberghs
Journal:  Ann Biomed Eng       Date:  2014-05-15       Impact factor: 3.934

Review 9.  Long-term efficacy and safety of botulinum toxin injections in dystonia.

Authors:  Juan Ramirez-Castaneda; Joseph Jankovic
Journal:  Toxins (Basel)       Date:  2013-02-04       Impact factor: 4.546

10.  The Effect of Botulinum Neurotoxin Serotype a Heavy Chain on the Growth Related Proteins and Neurite Outgrowth after Spinal Cord Injury in Rats.

Authors:  Ya-Fang Wang; Fu Liu; Jing Lan; Juan Bai; Xia-Qing Li
Journal:  Toxins (Basel)       Date:  2018-02-02       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.